PROM1 and endometrial cancer: Moreover, Shang et al. proposed a novel therapeutic approach by combining EGFR inhibition with NOTCH pathway targeting in CD133+ cells, aiming to enhance the efficacy of EGFR inhibitors in endometrial cancer [243].